Reversine: Aurora Kinase Inhibitor for Cancer Cell Cycle Research

Executive Summary: Reversine (6-N-cyclohexyl-2-N-(4-morpholin-4-ylphenyl)-7H-purine-2,6-diamine) is a selective, cell-permeable inhibitor of Aurora kinases A, B, and C, with IC50 values of 150 nM, 500 nM, and 400 nM, respectively (ApexBio). It blocks mitotic progression by disrupting centrosome maturation and spindle assembly. In vitro, Reversine induces dedifferentiation and suppresses proliferation in multiple cervical cancer cell lines. In murine models, it synergizes with aspirin to reduce tumor burden via apoptosis induction (Kaisaria et al., 2019). Reversine is insoluble in water but dissolves readily in DMSO and ethanol, making it suitable for diverse cell-based assays. These properties make Reversine a cornerstone tool for elucidating Aurora kinase signaling in cancer research.

Biological Rationale

Aurora kinases A, B, and C are serine/threonine kinases essential for mitotic regulation. They coordinate centrosome maturation, bipolar spindle formation, chromosome alignment, and segregation (Kaisaria et al., 2019). Dysregulation of Aurora kinases is linked to oncogenesis, aneuploidy, and tumor progression. Inhibition of these kinases disrupts the mitotic checkpoint complex (MCC), which ensures accurate chromosome segregation. Reversine targets the Aurora kinase signaling axis, providing a means to dissect the molecular control of cell division and its aberrations in cancer (see review).

Mechanism of Action of Reversine

Reversine is a synthetic purine analog that competitively inhibits the ATP-binding pocket of Aurora kinases. Its IC50 values are 150 nM (Aurora A), 500 nM (Aurora B), and 400 nM (Aurora C), measured under standard biochemical assay conditions at 25°C (ApexBio). By inhibiting these kinases, Reversine halts phosphorylation of substrates involved in mitotic spindle assembly and kinetochore function. This leads to MCC disassembly, inhibition of the anaphase-promoting complex/cyclosome (APC/C), and cell cycle arrest at the G2/M transition (Kaisaria et al., 2019). Reversine also induces dedifferentiation in murine myoblasts and apoptosis in human cervical cancer cell lines.

Evidence & Benchmarks

• Reversine exhibits IC50 values of 150 nM (Aurora A), 500 nM (Aurora B), 400 nM (Aurora C) in enzymatic assays (product data).
• In vitro, Reversine induces dedifferentiation in murine myoblasts (C2C12) at concentrations ≥1 μM, within 48 hours (Kaisaria et al., 2019).
• Reversine suppresses proliferation and induces apoptosis in HeLa, U14, Siha, Caski, and C33A cervical cancer cell lines at doses between 0.5–5 μM (internal review).
• In vivo, combined treatment of Reversine (dose-dependent, 1–10 mg/kg) and aspirin reduces tumor weight and volume in murine cervical cancer xenografts over 21 days (Kaisaria et al., 2019).
• Reversine is insoluble in water but dissolves in DMSO to ≥19.65 mg/mL and in ethanol to ≥6.69 mg/mL with warming and sonication (ApexBio).
• Storage at -20°C as a solid preserves activity; solutions are not recommended for long-term storage (ApexBio).

Applications, Limits & Misconceptions

Applications:

• Dissection of Aurora kinase function in mitotic checkpoint regulation (see detailed mechanism analysis—this article expands on translational benchmarks in cancer models).
• Investigation of cell cycle arrest, aneuploidy, and apoptosis in cancer cell lines.
• Synergistic anti-tumor strategies (e.g., Reversine plus aspirin) in preclinical models.
• Tool compound for screening resistance mechanisms to mitotic inhibitors.

Limits:

• Not selective for a single Aurora kinase isoform at higher concentrations.
• Limited solubility in aqueous buffers restricts direct use in some in vivo models.
• Intended for research use; not for diagnostic or clinical application.

Common Pitfalls or Misconceptions

• Reversine is not effective in water-based buffers due to insolubility; DMSO or ethanol must be used as solvents.
• Prolonged storage of Reversine solutions (>1 week) leads to degradation; always prepare fresh solutions for experiments.
• Reversine's anti-tumor effects are not universal; activity varies by cancer cell type and genetic background.
• It is not approved for human or veterinary therapeutic use.
• High concentrations may trigger off-target effects unrelated to Aurora kinase inhibition.

Workflow Integration & Parameters

Reversine is supplied as a solid and should be stored at -20°C. For cell-based assays, dissolve in DMSO to a stock concentration of 10–20 mM. Dilute stocks into culture media to achieve working concentrations (typically 0.1–10 μM), ensuring final DMSO does not exceed 0.1% (v/v). Ethanol can be used as an alternative solvent but may require gentle warming and sonication. Fresh working solutions should be prepared immediately prior to use. Avoid repeated freeze-thaw cycles. For in vivo studies, solubilize in DMSO or ethanol and dilute into vehicle suitable for injection (product instructions).

Conclusion & Outlook

Reversine is a validated Aurora kinase inhibitor that enables targeted disruption of mitotic checkpoints and cell cycle regulation in cancer models. Its nanomolar potency, combined with robust effects in cellular and animal systems, make it a preferred tool for dissecting Aurora kinase signaling and screening anti-mitotic agents. This article extends prior reviews by integrating recent in vivo synergy data and highlighting workflow best practices (cf. strategic overview). Ongoing research will clarify its utility in novel cancer models and resistance paradigms, further expanding its role in translational oncology.